
Lonza collaborates with Asher Biotherapeutics Inc
Asher Biotherapeutics is a developer of targeted immunotherapies for cancer, chronic viral infections and autoimmune disorders. AB248, Asher Bio’s...

Pfizer-Seagen: Acquisition in the works
As announced earlier this week, Pfizer Inc. plans to purchase Seagen for US$43bn. The Boards of Directors of both companies approved the transaction...

BioNTech bags Instadeep for £562m
According to Biontech, the acquisition is part of its strategy to "build world-leading capabilities in AI-driven drug discovery and the...

Collaboration to fight cancer
Cancer Research UK and UCB SA have announced to advance two cancer antibodies of the Brussels-based biopharma company to the clinical testing stage....

500 experts at the 7th AMR Conference in Basel
That antimicrobial resistance can no longer be considered a silent pandemic became abundantly clear at the AMR Conference in Basel from March 16-17....

€72M from Novo´s REPAIR Impact Fund for Group B Streptococcus vaccines
Group B Streptococcus (GBS) colonises globally about 15-25% of women and can cause life-threatening infections in newborns during the first months of...

Ethris inks €15m deal with Indian Ciplas
The investment is aimed at establishing a long-term strategic partnership until the end of Q1/2023 between Cipla and Ethris for the development of...